Business Wire

Alipay+ Expands Payments and Digital Ecosystem as Mobile Wallets Become a Catalyst for New Travel Habits and Inclusive Growth

Share

Alipay+ is Ant International’s global wallet gateway, enabling global merchants to accept payments from users of mobile wallets and digital banking apps around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007877113/en/

Alipay+ empowers travellers to make cross-border payments and access travel services directly with their home e-wallets

To empower global tourism, Alipay+ has significantly expanded its payments and digital services ecosystem, in three ways:

  • Payments: Growing cross-border payment acceptance for Alipay+ to more than 100 markets, and expanding its partner ecosystem to 40, representing 1.8 billion users
  • Partners: Supporting [new] Bluecode (Europe), PayPay (Japan) and KBank (Thailand) users to pay with their banking and wallet apps when traveling abroad
  • Services: New services include (i) Alipay+ Voyager, a built-in AI travel agent, integrating partners like Trip.com, Agoda and Grab, (ii) Alipay+ GenAI Cockpit, an AI-as-a-Service solution for digital wallets to build AI-native solutions, and (iii) Expanded Global Blue in-app tax refunds for more partners, creating an end-to-end digital experience

“Travel has a significant impact to local economies, and we believe that mobile wallets can be a catalyst for growth, connecting travellers and businesses in more ways than ever,” said Douglas Feagin, President of Ant International. “Alipay+ aims to support the travel ecosystem with AI-powered payments and digital services to enable online and offline merchants, tourism partners, and other fintechs to create customer-centric engagements for mobile-savvy consumers. Through greater collaboration, we can create a new future of travel, one that enhances the experience for consumers, and promotes growth and connectivity.

Mobile payments become the norm, driving inclusive growth for global merchants

Travellers are embracing the use of their trusted home payment app, with more than 6.5 million digital wallet users using Alipay+ cross-border payments for the first time in the first half of 2025. Transactions across online travel agents and in-store merchants increased by more than 30%1. Not only can travellers travel and pay “like a local” more conveniently, but now businesses can reach more customers easily.

To ensure inclusive growth at scale, Alipay+ is deepening its collaborations with national payment networks. Alipay+ transactions via national standardised QRs have almost doubled, as travellers can easily make payments at SMEs and merchants in smaller cities, including in destinations like South Korea, Malaysia, Singapore, Cambodia, Sri Lanka and more.

Short-haul, value-conscious travel on the rise, opening up more opportunities for local businesses

Travellers are seeking greater value when they travel by going to places closer to home, looking for deals, and spending at local merchants.

Asia is leading global travel growth in 2025, with intra-Asia travel a big contributor. China, Japan, South Korea, and particularly Southeast Asia are amongst the most popular travel destinations globally, with intra-Asia transactions by Alipay+ partners increasing 32 percent year-on-year.

Travellers want to save when they can, without compromising on experiencing local destinations. Redemptions via A+ Rewards, an in-app marketing platform where travellers can browse local promotions and coupons, increased 57 percent. Travellers are also spending more at local businesses, with transactions under USD10 increasing 37 percent.

While hotspots within Europe like France, Italy, Germany and the United Kingdom remain popular, destinations like Hungary, Greece and Norway saw the biggest growth in transactions, as travellers aim to explore new places while maximising their budgets.

Experiences and niche services in higher demand as travellers seek more conscious travel

Travellers are spending across more diverse travel scenarios beyond retail. While transactions for attractions and F&B continue to see significant growth, spending on local services including beauty, medical and education have become one of the key aspects of travel. For example, K-beauty transactions in South Korea increased 115 percent year-on-year.

Travellers are also going around more independently, with transactions on ride-hailing platforms doubling, and those on public transport increasing close to 50 percent. The expansion of Alipay+ acceptance across merchants and different modes of transportation has made it easier for travellers to visit smaller towns including Shikokuchūō in Japan, Jeollabuk-do in South Korea, Semporna in Malaysia and Phra Nakhon Si Ayutthaya Province in Thailand.

About Alipay+

Ant International's Alipay+ is a global wallet gateway with cross-border payment and digitisation services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.

1All Alipay+ data included are year-to-year comparison between H1 2025 and H1 2024

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007877113/en/

Contacts

Scott Lai, scott.lai@ant-intl.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye